Page 359 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 359
LP34 EXVIVO LIVER RESECTION AND AUTOTRANSPLANTATION: LATE BREAKER ePOSTERS
LP35 A FEASIBLE AND HIGHLY EFFECTIVE PROCEDURE
LP36 FOR PATIENTS WITH END-STAGE ALVEOLAR
LP37 ECHINOCOCCOSIS - 15 CASES EXPERIENCE
Hao Wen*, Jia-Hong Dong, Jin-Hui Zhang, Wei-Dong Duan,
Jin-Ming Zhao,Yu-Rong Liang,Ying-Mei Shao, Xue-Wen Ji,
Qin-Wen Tai, Tao Li, Hao Gu, Tuerhongjiang Tuxun,Yi-Biao He,
Jie-Fu Huang, China
A PLACEBO-CONTROLLED, MULTICENTER, DOUBLE-
BLIND, RANDOMISED, PHARMACOKINETIC AND
PHARMACODYNAMIC TRIAL OF EMRICASAN (IDN-6556)
IN SUBJECTS WITH ACUTE-ON CHRONIC LIVER FAILURE
(ACLF)
Rajiv Jalan*, Gavin Wright, Stuart McPherson, Catherine Frenette,
Matthew Cave, Mark Morris, Mira Huyghe, Gary Burgess,
The United Kingdom
UNDERSTANDING HEPATITIS DELTA VIRUS AND HBSAG
KINETICS DURING TREATMENT WITH PRENYLATION
INHIBITOR LONAFARNIB VIA MATHEMATICAL MODELING
Laetitia Canini, Christopher Koh, Scott J. Cotler, Xiongce Zhao,
Susan L. Uprichard, Vanessa Haynes-Williams, Mark A. Winters,
Gitanjali Subramanya, Stewart L. Cooper, Peter Pinto, Erin Wolff,
Rachel Bishop, Ma Ai Than Han, David E. Kleiner, Onur Keskin,
Ramazan Idilman, Cihan Yurdaydin, Jeffrey S. Glenn, Theo Heller,
Harel Dahari*, The United States
A PLACEBO-CONTROLLED, MULTICENTER, DOUBLE-
BLIND, RANDOMISED TRIAL OF EMRICASAN IN SUBJECTS
WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
AND RAISED TRANSAMINASES
Mitchell Shiffman*, Bradley Freilich, Raj Vuppalanchi, Kymberly Watt,
Gary Burgess, Mark Morris, Beth Sheedy, Eugene Schiff,
The United States
Vienna, Austria • April 22–26, 2015 359
LP35 A FEASIBLE AND HIGHLY EFFECTIVE PROCEDURE
LP36 FOR PATIENTS WITH END-STAGE ALVEOLAR
LP37 ECHINOCOCCOSIS - 15 CASES EXPERIENCE
Hao Wen*, Jia-Hong Dong, Jin-Hui Zhang, Wei-Dong Duan,
Jin-Ming Zhao,Yu-Rong Liang,Ying-Mei Shao, Xue-Wen Ji,
Qin-Wen Tai, Tao Li, Hao Gu, Tuerhongjiang Tuxun,Yi-Biao He,
Jie-Fu Huang, China
A PLACEBO-CONTROLLED, MULTICENTER, DOUBLE-
BLIND, RANDOMISED, PHARMACOKINETIC AND
PHARMACODYNAMIC TRIAL OF EMRICASAN (IDN-6556)
IN SUBJECTS WITH ACUTE-ON CHRONIC LIVER FAILURE
(ACLF)
Rajiv Jalan*, Gavin Wright, Stuart McPherson, Catherine Frenette,
Matthew Cave, Mark Morris, Mira Huyghe, Gary Burgess,
The United Kingdom
UNDERSTANDING HEPATITIS DELTA VIRUS AND HBSAG
KINETICS DURING TREATMENT WITH PRENYLATION
INHIBITOR LONAFARNIB VIA MATHEMATICAL MODELING
Laetitia Canini, Christopher Koh, Scott J. Cotler, Xiongce Zhao,
Susan L. Uprichard, Vanessa Haynes-Williams, Mark A. Winters,
Gitanjali Subramanya, Stewart L. Cooper, Peter Pinto, Erin Wolff,
Rachel Bishop, Ma Ai Than Han, David E. Kleiner, Onur Keskin,
Ramazan Idilman, Cihan Yurdaydin, Jeffrey S. Glenn, Theo Heller,
Harel Dahari*, The United States
A PLACEBO-CONTROLLED, MULTICENTER, DOUBLE-
BLIND, RANDOMISED TRIAL OF EMRICASAN IN SUBJECTS
WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
AND RAISED TRANSAMINASES
Mitchell Shiffman*, Bradley Freilich, Raj Vuppalanchi, Kymberly Watt,
Gary Burgess, Mark Morris, Beth Sheedy, Eugene Schiff,
The United States
Vienna, Austria • April 22–26, 2015 359
